Re-Do Coronary Artery Bypass Surgery

CHAPTER 90 Re-do Coronary Artery Bypass Surgery

Reoperations present coronary surgeons with their greatest challenges. Patients undergoing reoperation for bypass grafting are different from those who undergo primary surgery. In addition to the risks of a repeated median sternotomy, their coronary artery and noncardiac atherosclerosis is more advanced, noncardiac comorbidities are more common, ventricular function is more likely to be abnormal, and the vascular pathologic processes that jeopardize myocardium are distinct and varied.14 All of these issues present specific technical challenges.

In addition to the technical difficulties reoperations present, decision-making is not perfectly straightforward. No major randomized trials have studied patients with prior bypass surgery. In only a few situations do observational studies indicate that reoperative coronary surgery improves prognosis.5 For many patients, percutaneous intervention is an appealing prospect, but unfortunately the results of percutaneous treatment of patients with prior surgery have been suboptimal even in the era of drug-coated stents.68

The reasons that patients need coronary reoperations have their anatomic bases in an ineffective first operation, bypass graft failure (early or late), progression of atherosclerosis in native coronary arteries, failure of interventional procedures, and combinations of these problems. The relative contributions of these factors have changed with the evolution of bypass surgery and with the evolution of alternative treatments for coronary atherosclerosis. Today, early vein graft failure, although not rare, is rarely an indication for early reoperation. First, percutaneous interventions are usually available to treat symptomatic patients who experience vein graft failure; and second, as long as an internal thoracic artery (ITA) to left anterior descending (LAD) graft is functioning, sufficient indications for early reoperation are rarely present even if other grafts are imperfect. Early reoperations are usually indicated only in the situation of both ITA and vein graft failure. Late reoperations are usually indicated by a combination of progression of native vessel atherosclerosis and vein graft failure, usually based on the occurrence of vein graft atherosclerosis.

The pathologic changes of vein grafts are important, not only as causes of reoperations but also as causes of events associated with medical or interventional treatment.9,10 Early vein graft occlusion is usually associated with intimal disruption and thrombosis. Within 2 to 3 months of surgery, a proliferative intimal fibroplasia develops in most vein grafts. This is a concentric, diffuse, and cellular lesion that becomes more fibrous with time. It usually does not cause stenosis or occlusion. Within a few years of operation, lipid deposition may occur in association with intimal fibroplasia; the resulting lesion is termed vein graft atherosclerosis. The fully developed lesion of vein graft atherosclerosis is very different from native vessel atherosclerosis. Vein graft atherosclerosis is superficial, nonencapsulated, diffuse, and concentric. It is an extremely friable lesion and is much more prone to embolization than is native vessel atherosclerosis. In addition, clinical studies appear to show that it is more consistently progressive than is true of native vessel atherosclerosis as vein graft stenoses caused by vein graft atherosclerosis predict a high level of clinical events. Patients with coronary risk factors such as hyperlipidemia and diabetes appeared to experience an increased incidence of vein graft atherosclerosis and graft failure.11 There is now evidence that treatment with platelet inhibitors and statins decreases the rate of late vein graft failure. However, even with these measures, vein graft atherosclerosis has not been eliminated.

ITA grafts rarely develop atherosclerosis, and the patency rate of ITA grafts, particularly to the LAD coronary artery, exceeds that of vein grafts.11 The use of ITA to LAD grafts at primary operations clearly decreases the risk of reoperation during the first 10 postoperative years, and the use of both ITA grafts further decreases the risk of reoperation (Fig. 90-1).4,12,13 Furthermore, although patent ITA grafts present technical challenges at reoperation, atherosclerotic embolization is not a risk as it is for patients with patent but atherosclerotic vein grafts.

For patients undergoing primary bypass surgery, the likelihood of undergoing a reoperation will depend on the length of their life, the severity of the atherogenic diathesis and the effectiveness of the treatment of that diathesis, the details of the primary operation, the alternative therapies available, and the physician’s and patient’s preferences. Review of patients undergoing primary bypass surgery at the Cleveland Clinic in the 1971-1974 time frame documented a 25% chance of reoperation by 20 postoperative years.14 Today we would expect that figure to be much less as the number of isolated coronary reoperations performed has declined. The Society of Thoracic Surgeons database noted 16,091 isolated coronary reoperations reported in 1998 compared with 9587 in 2007.15


The randomized trials of bypass surgery versus medical management did not include patients with previous surgery. Furthermore, patients with previous surgery are extremely heterogeneous, their vascular pathologic processes being multiple and their extent of revascularization not always falling into the categories of single-, double-, and triple-vessel disease. In particular, vein graft atherosclerosis is a more progressive vascular disease, and the presence of vein graft atherosclerosis predicts a particularly unfavorable clinical outcome without repeated surgery. Thus, there is relatively little clarity in terms of the indications for reoperation. Observational studies, however, have provided some important information.

Early stenoses in vein grafts (<5 years after operation) do not predict unfavorable outcomes if patients are not highly symptomatic.5,10 Therefore, an early stenosis in a vein graft is not necessarily an indication for either reoperation or re-intervention.

As has been true of patients undergoing primary bypass surgery, functional studies may add to the accuracy of identifying those patients likely to have unfavorable outcomes without reoperation. Patients who demonstrate ischemia and an impaired exercise capacity are at more risk for death and cardiac events without reoperation than are those with negative or only mildly positive stress test results.16


In the absence of contraindications, all patients with previous bypass surgery should be treated with platelet inhibitors, statin-type drugs, and control of risk factors including hypertension, diabetes, and hyperlipidemia. The indications for more invasive treatment are related to symptom relief and, in some circumstances, improvement of prognosis.

Significant late stenoses in multiple vein grafts or in a vein graft to the LAD coronary artery predict an unfavorable prognosis that can be improved by reoperation and therefore constitute a strong indication for repeated surgery. The indications for reoperation in these anatomic situations are particularly strong when they are associated with abnormal left ventricular function, a positive stress test result, and a clear demonstration of myocardium in jeopardy. The presence of multivessel disease jeopardized by native vessel lesions and vein graft disease that includes a proximal LAD lesion also seems, on the basis of logic, to constitute an indication for reoperation for improvement of prognosis. There has not yet been a clear demonstration that reoperation improves the survival rate of patients who have a patent, effective ITA-LAD graft. Severe symptoms of angina combined with severe stenoses in native coronary arteries or grafts subtending areas of viable myocardium constitute good indications for surgery for the purpose of symptom relief.

The availability of percutaneous coronary treatments can be an advantage in the symptomatic treatment of patients with previous bypass surgery. Native vessel disease in particular, when accessible, can be effectively treated with stenting, and in the current era of drug-coated stents, it is often effective. The treatment of vein graft disease with percutaneous intervention has, unfortunately, not been effective in the long term even with the use of drug-coated stents.8,1719 However, despite those issues, it is still reasonable to use stenting for treatment of symptomatic vein graft disease when large amounts of myocardium are not jeopardized and symptom relief is the goal. There is no evidence that the treatment of vein graft disease with percutaneous treatment achieves any improvement in prognosis in any situation.

Comparisons of surgical and percutaneous treatments for heterogeneous groups of patients with previous bypass surgery have shown roughly equivalent outcomes. However, these studies have been small in number and have not separated patients into subsets based on the vascular pathologic process needing to be treated and prognostic subgroups based on coronary and vein graft anatomy. Therefore, the relative use of reoperation and percutaneous coronary treatment for the anatomic treatment of patients with previous bypass surgery will depend on multiple factors, including the vascular pathologic process producing the ischemia, the general health of the patient and specific contraindications to surgery, the function of the left ventricle, the area of myocardium in jeopardy, and the experience of the surgical and interventional teams.

< div class='tao-gold-member'>

Jul 30, 2016 | Posted by in CARDIAC SURGERY | Comments Off on Re-Do Coronary Artery Bypass Surgery
Premium Wordpress Themes by UFO Themes